TapewireFind a company

person · Reporting owner

Eldridge George A

Disclosed activity across 1 company

Tapewire entity
89879
SEC CIK
0001413006

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Jade Biosciences, Inc.AVTE · Entity 4757SEE REMARKSJune 14, 2024June 14, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Jade Biosciences, Inc.

Report date June 14, 2024 · Filed June 14, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect20,022 Reported balance After 2024-06-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2024-06-14 · Exercise / conversion · Acquired 15,000 · Balance 20,022

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).

Common StockSEC Table I · non-derivativeDirect5,022 Reported balance After 2024-06-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 2 · 2024-06-14 · Sale · Disposed 15,000 · Balance 5,022

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-04-01Direct28,763 Reported balance After 2024-06-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-06-14 · Exercise / conversion · Disposed 15,000 · Balance 28,763

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F3: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.

F2: Includes 3,062 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on April 30, 2024 in a transaction that is exempt under Rule 16b-3(c) and 16b3(d).

F3: A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 23, 2022 Filed Nov 28, 2022 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 1,261 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-011794 · form4-11282022_051101.xml · derivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,378

Underlying: Common Stock · 1,261 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F3 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 23, 2022 Filed Nov 28, 2022 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 1,261 $19.07 $24,048.28
Disclosure

SEC source: 0001415889-22-011794 · form4-11282022_051101.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.40, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 23, 2022 Filed Nov 28, 2022 22:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 1,261 $2.14 $2,698.54
Disclosure

SEC source: 0001415889-22-011794 · form4-11282022_051101.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,221

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
November 22, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 174 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · derivative · entry 10

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,639

Underlying: Common Stock · 174 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 22, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 174 $19.01 $3,308.11
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 7

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.03, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 22, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 174 $2.14 $372.36
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 6

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,134

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
November 21, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 2 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · derivative · entry 9

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,813

Underlying: Common Stock · 2 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 21, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 2 $19.00 $38.00
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 5

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
November 21, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 2 $2.14 $4.28
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 4

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,962

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

Read SEC document
November 18, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionStock Option (Right to Buy) · Derivative 861 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · derivative · entry 8

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,815

Underlying: Common Stock · 861 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F6 · derivative.exercise_date: A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
November 18, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 81 $20.13 $1,630.81
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 3

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,960

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.095 to $20.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 18, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 SaleCommon Stock 780 $19.45 $15,174.20
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 2

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,041

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.06 to $20.045, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 18, 2022 Filed Nov 23, 2022 01:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 Exercise / conversionCommon Stock 861 $2.14 $1,842.54
Disclosure

SEC source: 0001415889-22-011708 · form4-11222022_081101.xml · nonDerivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,821

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.

F2 · balance_after: Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).

Read SEC document
December 14, 2021 Filed Dec 16, 2021 23:00 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 65,433 $0.00 Strike: $10.61 $0.00
Disclosure

SEC source: 0001493152-21-031752 · ownership.xml · derivative · entry 1

Eldridge George A · CIK 0001413006 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,433

Underlying: Common Stock · 65,433 shares

Expires 2031-12-13

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 22:29 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 76,900 $0.00 Strike: $14.00 $0.00
Disclosure

SEC source: 0001104659-21-088375 · tm2121189-2_4seq1.xml · derivative · entry 3

Eldridge George A · CIK 0001413006 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,900

Underlying: Common Stock · 76,900 shares

Expires 2031-06-28

F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 29, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Read SEC document
April 02, 2021 Filed Jul 1, 2021 22:29 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 98,676 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001104659-21-088375 · tm2121189-2_4seq1.xml · derivative · entry 2

Eldridge George A · CIK 0001413006 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,676

Underlying: Common Stock · 98,676 shares

Expires 2031-04-01

F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

Read SEC document
April 02, 2021 Filed Jul 1, 2021 22:29 UTC Jade Biosciences, Inc. AVTE · Entity 4757 GrantStock Option (Right to Buy) · Derivative 50,850 $0.00 Strike: $2.14 $0.00
Disclosure

SEC source: 0001104659-21-088375 · tm2121189-2_4seq1.xml · derivative · entry 1

Eldridge George A · CIK 0001413006 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,850

Underlying: Common Stock · 50,850 shares

Expires 2031-04-01

F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on March 22, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.